All participants – Page 14 – Communicable Diseases Research

Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic

도미니카 공화국의 핫스팟 커뮤니티에서 SARS-CoV-2에 대한 특정 항체의 혈청 유병률

Articles

Published on 2020-12-212022-09-12
Journal: The American Journal of Tropical Medicine and Hygi [Category] MERS, SARS, 진단,

Perceived Effectiveness, Safety, and Attitudes Toward the Use of Nucleic Tests of SARS-CoV-2 Among Clinicians and General Public in China

중국의 임상의와 일반 대중 사이에서 SARS-CoV-2의 핵 검사 사용에 대한 인식된 효과, 안전성 및 태도

Public Health

Published on 2020-12-172022-09-11
Journal: Frontiers in Public Health [Category] MERS, SARS, 진단, 치료기술,

[키워드] Accuracy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 All participant All participants approval Attitude biomedicine China Chinese Compliance conducted coronavirus coronavirus disease Coronavirus disease 2019 Coverage COVID-19 cross-sectional cross-sectional study Efficacy Epidemic female IMPROVE knowledge Likert scale majority Novel coronavirus nucleic test pandemic participant Perceived positive positive attitude Public questionnaire recruited Research research and development respiratory Safety SARS-CoV-2 SARS-CoV-2 virus severe acute respiratory syndrome Coronavirus tension Test test kits the SARS-CoV-2 virus was obtained were measured
[DOI] 10.3389/fpubh.2020.599862 PMC 바로가기 [Article Type] Public Health

Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial

성인의 중증 COVID-19 치료를 위한 분무형 계면활성제(COV-Surf): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Randomized Controlled Trial

Published on 2020-12-102022-09-10
Journal: Trials [Category] MERS, SARS, 비임상, 임상,

[키워드] 1080 24 hour 24 hours 48 hour 48 hours ACE2 ADEs administration Adverse adverse event adverse events AEs ALEA All participant All participants allergy alveolar angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 anticipated attending physician bind Blinding block randomization Blood bovine breath buffer calcium cells cellular cholesterol Chronic kidney disease class clinical Clinical improvement clinical trial clinical trials Cohort Combination comparator Compliance Concentration conducted Consent contraindication contributing to Control control arm controls COVID-19 COVID-19 adult patient COVID-19 patients current cytokine Data collection Data monitoring committee death declined defined delivery described Device dialysis discretion dissemination dose drug Effect Efficacy EGFR element Eligible participants end point End-Expiratory Pressure Endotracheal intubation enrolled Enrollment enrolment epithelial Escalation EudraCT evaluate exclusion exclusion criteria expected fatty Fatty acid feasibility free fatty acid Frequency hospital hospitalised hypoxia impair include inclusion criteria index Inflammatory marker inflammatory markers Inflammatory response intensive care intensive care unit Intervention investigator Kidney disease lack liver liver failure Local lung lung lavage mechanical ventilation mechanical ventilator mechanically ventilated patient mechanically ventilated patients mixture Mortality nebulisation number objective Open-label opinion Ordinal Scale other treatment outcome oxidative stress Oxygenation PaO participant Patient PCR PEEP Phosphatidylcholine phosphatidylethanolamine phosphatidylglycerol phosphatidylinositol phospholipid PIP Placebo plasma Pneumothorax Positive end-expiratory pressure Prevent Primary outcome progression Protein protocol pulmonary compliance pulmonary hemorrhage pulmonary ventilation quantification randomisation randomised randomised controlled trial Randomized Randomized controlled trial reached receive recorded recruitment reduction Registered reported Respiratory failure SAEs Sample size SARS-CoV-2 viral load SARS-CoV-2 virus secondary outcome Secondary outcomes Serious Adverse Events severe COVID-19 severity sphingomyelin Stage Standard Standard of care status Study protocol subject supplementary material surface tension surfactant synthesis tension the WHO tissue damage total sample size tracheal tracheal aspirate Tracheal aspirates transfer Treatment Trial Trial Steering Committee turnover unique university University College London usual standard of care Ventilation Ventilation Index ventilatory support VFD vibrating mesh nebulizer Viral Viral load virus water website weight with COVID-19 worsening
[DOI] 10.1186/s13063-020-04944-5 PMC 바로가기 [Article Type] Randomized Controlled Trial

6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort

티롤리안 COVID-19 코호트에서 6개월 SARS-CoV-2 항체 지속성

Original Article

Published on 2020-12-092022-09-10
Journal: Wiener Klinische Wochenschrift [Category] MERS, SARS, 진단, 치료기술, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus age All participant All participants Anti-viral anti-viral antibody antibody antibody response against Antibody testing Arthritis average binding antibody caused convalescent coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 cohort cut-off cut-off point decrease Diagnosis disease disease onset dropped ELISA except for Follow-up healthy Hyposmia identify Immunity immunized individuals Infection information life Neutralizing Neutralizing antibodies neutralizing antibody participant Prospective Receptor binding domain respiratory Result rheumatoid arthritis S1 subunit SARS-CoV-2 antibody severe acute respiratory syndrome Coronavirus specificity Spike protein the S1 subunit the spike protein titers virus were used
[DOI] 10.1007/s00508-020-01795-7 PMC 바로가기 [Article Type] Original Article

Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience

인간 백혈구 항원 복합체 및 기타 면역유전학적 및 임상적 요인은 SARS-CoV-2 감염에 대한 감수성 또는 보호 및 질병 경과의 중증도에 영향을 미칩니다. 사르데냐 체험

Randomized Controlled Trial

Published on 2020-12-042022-08-13
Journal: Frontiers in Immunology [Category] MERS, SARS, 유전자 메커니즘, 임상, 진단,

[키워드] 95% CI All participants allele alleles analyzed Asymptomatic asymptomatic or pauci-symptomatic patients Autoimmune disease Autoimmune diseases beta-thalassemia beta-thalassemia trait beta-thalassemic trait Care carried clinical Clinical data Clinical outcome clinical, genetic and immunogenetic factors collected controls Course COVID-19 severity deficiency Demographic and clinical data disease course DRB1 evaluate experience extended haplotype Factor Frequency G6PDH G6PDH deficiency Genetic genetic factor genetic factors Genetic polymorphism Glucose Glucose-6-phosphate glucose-6-phosphate dehydrogenase haplotype frequencies haplotypes health problem healthy HLA allele HLA class I HLA class I and II molecules HLA-A HLA-A*02:05, B*58:01, C*07:01 HLA-A*30:02 HLA-A*30:02, B*14:02, C*08:02 HLA-C HLA-C*04:01 allele HLA-DRB1*08:01 allele home care home care patients hospital hospital care hospitalized patient hospitalized patients Human human leukocyte antigen immunogenetic background immunogenetic factors in-patient infections influence Influenza influenza vaccination Italy Male sex material Mild disease negative influence Older age Other Participants Pathogenesis Patient patients pauci-symptomatic phosphate predisposing factor protection protective effect public health recruited related clinical consequence related clinical consequences required Result Sardinia Sardinian Sardinian control Sardinian population SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 patients seasonal flu severe disease Sex susceptibility Taking thalassemia the disease three-loci haplotype vaccination with mild disease without symptoms world-wide public health problem
[DOI] 10.3389/fimmu.2020.605688 PMC 바로가기 [Article Type] Randomized Controlled Trial

The effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19): A structured summary of a study protocol for a randomised controlled trial

코로나바이러스(COVID-19) 환자의 임상 증상에 대한 프로폴리스 보충제의 효과: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Randomized Controlled Trial

Published on 2020-12-032022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 age All participants anticipated Arm baseline Blinding block size calculated categories Cellulose changes in clinical clinical symptom Clinical symptoms Clinicians color concealed control group coronavirus coronavirus disease COVID-19 Date dissemination double-blind element eligible hospital Intervention intervention group investigator investigators Iran labelling microcrystalline microcrystalline cellulose name number objective odor outcome Parallel Arm participant Participants Patient patients PCR test performed pharmaceutical phase Placebo placebo-controlled clinical trial Propolis protocol Protocol study provided randomised controlled trial randomization randomization list randomization sequence Randomized Randomly receive recruited Registered registration number Reyhan Sample size sealed sensitivity sequence severity Sex shape stratified Study protocol supplementary material Tablet Taste total sample size Trial Trial registration Version Warfarin website weight
[DOI] 10.1186/s13063-020-04934-7 PMC 바로가기 [Article Type] Randomized Controlled Trial

Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants

다른 위험 요소가 없는 경우 고령이 COVID-19 사망률과 관련이 있습니까? 470,034명의 참가자를 대상으로 한 일반 인구 코호트 연구

Research Article

Published on 2020-11-052022-08-13
Journal: PLoS ONE [Category] COVID-19, Medicine and Health Sciences, MERS, SARS,

[키워드] 95% CI absence age All participants association baseline baseline data cohort study COVID-19 COVID-19 mortality current deaths died Eligible participants expiratory explained Factor forced expiratory volume high systolic blood pressure higher risk increased mortality independent risk factor Low forced expiratory volume low handgrip strength mediators Mortality mortality risk much lower multiple long-term condition multiple long-term conditions Older Older adults Older age participant Participants Poisson regression reported Result risk risk factor Risk factors Systolic blood pressure UK biobank Volume was used with COVID-19
[DOI] 10.1371/journal.pone.0241824 PMC 바로가기 [Article Type] Research Article

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-132022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

HIV에 감염되지 않은 건강한 성인을 대상으로 한 두 가지 이종 HIV 백신 요법의 안전성 및 면역원성(TRAVERSE): 무작위 배정, 병렬 그룹, 위약 대조, 이중 맹검, 1/2a상 연구

Articles

Published on 2020-09-302022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] 95% CI Ad26 Adenovirus Administered advancement adverse event adverse events aligned All participant All participants Analysis Antigen antigens applied assigned binding antibodies binding antibody blood sample breadth CD4+ T-cell clade collected computer-generated Defense Deltoid muscle Department diagnosed dose double-blind Efficacy elicit Eligible participants ELISpot responses enrolled finding first vaccination foundation funding group groups healthy Heterologous HIV HIV infection HIV vaccine HIV-1 infection HIV-uninfected IFNγ ELISPOT response IFNγ ELISPOT responses IgG immune response immune responses Immunity immunogenicity injection Intramuscular injection investigator investigators Jackson janssen Laboratory Local magnitude median medical history Medicine Melinda Gate Melinda Gates Military Medicine mononuclear cell mononuclear cells opinion Other parallel-group participant PBMC PBMCs per protocol per-protocol Peripheral blood Peripheral blood mononuclear cells Physical examination Placebo placebo group placebo-controlled placebos prevention randomisation randomised Randomly randomly permuted block randomly permuted blocks regimen regimens Registered repeated risk Safe Safety second vaccination Sponsor stratified subgroups systemic reactogenicity T-cell Response tested tetravalent the placebo group titre titres Tolerability treatment allocation Trial trivalent USA vaccination vaccination schedule Vaccinations Vaccine vaccine group vectored vaccine vital sign was done with HIV
[DOI] 10.1016/S2352-3018(20)30229-0 PMC 바로가기 [Article Type] Articles

Effect of an E-Learning Module on Personal Protective Equipment Proficiency Among Prehospital Personnel: Web-Based Randomized Controlled Trial

병원 전 직원의 개인 보호 장비 숙련도에 대한 E-Learning 모듈의 효과: 웹 기반 무작위 대조 시험

Original Paper

Published on 2020-08-212022-08-13
Journal: Journal of Medical Internet Research [Category] MERS, 임상,

[키워드] added All participant All participants baseline both groups Care communication confidence Contamination control group Controlled coronavirus coronavirus disease COVID-19 demonstration donning sequence e-learning group e-learning module Effect effective effective communication electronic learning eligible email equipment evaluate for inclusion gamified gamified e-learning module groups Health Health care IMPROVE in both group infection control Infection control guidelines Intervention investigators IQR knowledge misuse module no significant difference objective online learning outcome assessors pandemic participant Participants Personal protective equipment PPE prehospital preintervention proportion protection Randomized Randomized controlled trial Result risk Safety second set shown significantly statistically significant Switzerland the median Trial web-based study Work environment
[DOI] 10.2196/21265 PMC 바로가기 [Article Type] Original Paper